AstraZeneca Annual Report and Form 20-F Information 2011

Financial StatementsConsolidated Statement of Comprehensive Incomefor the year ended 31 DecemberRevenue 1 33,591 33,269 32,804Cost of sales (6,026) (6,389) (5,775)Gross profit 27,565 26,880 27,029Distribution costs (346) (335) (298)Research and development 2 (5,523) (5,318) (4,409)Selling, general and administrative costs 2 (11,161) (10,445) (11,332)Profit on disposal of subsidiary 2, 22 1,483 – –Other operating income and expense 2 777 712 553Operating profit 2 12,795 11,494 11,543Finance income 3 552 516 462Finance expense 3 (980) (1,033) (1,198)Profit before tax 12,367 10,977 10,807Taxation 4 (2,351) (2,896) (3,263)Profit for the period 10,016 8,081 7,544Other comprehensive income:Foreign exchange arising on consolidation (60) 26 388Foreign exchange differences on borrowings forming net investment hedges 24 101 (68)Amortisation of loss on cash flow hedge 2 1 1Net available for sale gains taken to equity 31 4 2Actuarial loss for the period 18 (741) (46) (569)Income tax relating to components of other comprehensive income 4 198 (61) 192Other comprehensive income for the period, net of tax (546) 25 (54)Total comprehensive income for the period 9,470 8,106 7,490Notes2011$m2010$m2009$mProfit attributable to:Owners of the Parent 9,983 8,053 7,521Non-controlling interests 33 28 23Total comprehensive income attributable to:Owners of the Parent 9,428 8,058 7,467Non-controlling interests 42 48 23Basic earnings per $0.25 Ordinary Share 5 $7.33 $5.60 $5.19Diluted earnings per $0.25 Ordinary Share 5 $7.30 $5.57 $5.19Weighted average number of Ordinary Shares in issue (millions) 5 1,361 1,438 1,448Diluted weighted average number of Ordinary Shares in issue (millions) 5 1,367 1,446 1,450Dividends declared and paid in the period 21 3,752 3,494 3,026All activities were in respect of continuing operations.$m means millions of US dollars.142 Financial StatementsAstraZeneca Annual Report and Form 20-F Information 2011